Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors

Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Research Study Number 20160860
Principal Investigator Scott Tykodi, MD
Phase I/II

Research Study Description

This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20160860
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Kidney Cancer; Lung Cancer; Melanoma; Renal Cancer; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Urogenital Neoplasms; Urologic Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Solid Organ Transplant (SOT); Neoplasms, Bronchial; Neoplasms, Respiratory Tract; Neoplasms, Thoracic; Carcinoma, Renal Cell

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials